跳至主要内容
临床试验/NCT02710292
NCT02710292已完成不适用

Clinical Evaluation of DAILIES TOTAL 1® in Japanese Population - Comparison of Lens Centration Between DAILIES TOTAL 1® and 1-DAY ACUVUE® TruEye®

Alcon Research1 个研究点 分布在 1 个国家目标入组 104 人开始时间: 2016年4月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
104
试验地点
1
主要终点
Percentage of Subjects With Investigator-rated Lens Centration of "Optimal" After 10 Days of Wear

研究概览

简要总结

The purpose of this study is to compare DAILIES TOTAL1® (DT1) to 1-DAY ACUVUE® TruEye® (TE) for Investigator-rated successful lens centration in Japanese population.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Must sign an informed consent form;
  • •Habitual current daily disposable soft contact lenses wearer;
  • •Symptoms of contact lens discomfort as defined by the Symptomatology (Eligibility) Questionnaire;
  • •Lenses within the power range specified in the protocol;
  • •Vision correctable to 20/25 or 0.1 logMAR (logarithmic minimum angle of resolution) or better in each eye at distance with pre-study contact lenses at Visit1;
  • •Acceptable lens fit with both study contact lenses;
  • •Willing to wear lenses every day or at least for a minimum of 10 days, 6 hours per day, every day if possible and attend all study visits;
  • •Other protocol-specified inclusion criteria may apply.

排除标准

  • •Currently wearing DT1 or TE sphere lenses;
  • •Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear;
  • •Use of systemic or ocular medications in which contact lens wear could be contraindicated as determined by the investigator;
  • •Eye injury or surgery within 12 weeks immediately prior to enrollment;
  • •History of herpetic keratitis, ocular surgery or irregular cornea;
  • •Prior refractive surgery;
  • •Monocular (only 1 eye with functional vision) or fit with only 1 lens;
  • •Participation in any clinical trial within 30 days of the enrollment visit;
  • •Other protocol-specified exclusion criteria may apply.

研究组 & 干预措施

DT1, then TE

Other

Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.

干预措施: Delefilcon A contact lenses (Device)

DT1, then TE

Other

Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.

干预措施: Narafilcon A contact lenses (Device)

TE, then DT1

Other

Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.

干预措施: Delefilcon A contact lenses (Device)

TE, then DT1

Other

Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.

干预措施: Narafilcon A contact lenses (Device)

结局指标

主要结局

Percentage of Subjects With Investigator-rated Lens Centration of "Optimal" After 10 Days of Wear

时间窗: Day 10, each product

Lens centration was assessed by the investigator on a 5-point scale, where 0=Optimal and 4=Severe decentration (with corneal exposure). Both eyes contributed to the analysis.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验